HRP20150317T1 - Peptidi trave za cjepivo - Google Patents
Peptidi trave za cjepivo Download PDFInfo
- Publication number
- HRP20150317T1 HRP20150317T1 HRP20150317TT HRP20150317T HRP20150317T1 HR P20150317 T1 HRP20150317 T1 HR P20150317T1 HR P20150317T T HRP20150317T T HR P20150317TT HR P20150317 T HRP20150317 T HR P20150317T HR P20150317 T1 HRP20150317 T1 HR P20150317T1
- Authority
- HR
- Croatia
- Prior art keywords
- segment
- polypeptide consisting
- polypeptide
- preparation
- grass
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 22
- 244000025254 Cannabis sativa Species 0.000 title claims 4
- 101100449439 Drosophila melanogaster grass gene Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 4
- 206010048908 Seasonal allergy Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000013574 grass pollen allergen Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
Claims (15)
1. Pripravak za uporabu u sprječavanju i liječenju alergije na travu, naznačen time, da se pripravak sastoji od:
(a) polipeptida koji se sastoji od odsječka KIPAGELQIIDKIDA ili njihove inačice,
(b) polipeptida koji se sastoji od odsječka SGKAFGAMAKKGQED ili njihove inačice, i
(c) polipeptida koji se sastoji od odsječka LKKAVTAMSEAEK ili njihove inačice, pri čemu je rečena inačinca duži polipeptid sastavljen od najviše 30 aminokiselina u dužini koji sadrži odsječak naveden pod
(a), (b) ili (c).
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da sadrži najmanje jednu rečenu inačicu polipeptida u dužini od 20 aminokiselina.
3. Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da sadrži najmanje jednu rečenu inačicu polipeptida u dužini od 17 aminokiselina.
4. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je (a) polipeptid koji se sastoji od odsječka KKIPAGELQIIDKIDA.
5. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da dalje sadrži:
(d) polipeptid koji se sastoji od odsječka PEVKYAVFEAALTKAIT ili njihovih inačica,
(e) polipeptid koji se sastoji od odsječka FIPMKSSWGA ili njihovih inačica, i
(f) polipeptida koji se sastoji od odsječka KSSWGAIWRIDPKKPLK ili njihovih inačica, pri čemu rečena inačica je duži polipeptid od najviše 30 aminokiselina koji sadrži odsječak koji je naveden pod (d), (e) ili (f).
6. Pripravak u skladu s patentnim zahtjevom 5, naznačen time, da je (d) polipeptid koji se sastoji od odsječka KPEVKYAVFEAALTKAIT.
7. Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da sadrži:
(a) polipeptid koji se sastoji od odsječka KKIPAGELQIIDKIDA,
(b) polipeptid koji se sastoji od odsječka SGKAFGAMAKKGQED,
(c) polipeptid koji se sastoji od odsječka LKKAVTAMSEAEK,
(d) polipeptid koji se sastoji od odsječka KPEVKYAVFEAALTKAIT,
(e) polipeptid koji se sastoji od odsječka FIPMKSSWGA,
(f) polipeptid koji se sastoji od odsječka KSSWGAIWRIDPKKPLK, i
(g) polipeptid koji se sastoji od odsječka KYDAYVATLTEALR.
8. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je isti otopina u kojoj je koncentracija svakog polipeptida u opsegu od 0.03 do 200 nmol/ml.
9. Pripravak u skladu s patentnim zahtjevom 8, naznačen time, da je koncentracija svakog polipeptida u opsegu od 5 do 200 nmol/ml.
10. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, daje isti farmaceutski pripravak koji sadrži farmaceutski prihvatljiv nosač ili otapalo.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time, da je pripravljen za oralnu primjenu, vanjsku, nazalnu primjenu, potkožnu primjenu, podjezičnu primjenu, intradermalnu primjenu, bukalnu primjenu, epidermalnu primjenu ili u obliku naljepaka ili za primjenu putem inhalacija ili injekcija.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 10 ili 11, naznačen time, da se koristi u postupku sprječavanja ili liječenja alergije na travu.
13. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 12, naznačen time, da se rečeni postupak koristi za sprječavanje ili liječenje alergije na travu kod ljudi.
14. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 13, naznačen time, da su ljudi oni koji su alergični na travu.
15. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 14, naznačeno time, da su rečeni ljudi:
- oni koji su osjetljivi na jednu ili više vrsta alergena polena trave;
- oni koji u imaju alergiju na travu zabilježenu u obiteljskoj povijesti; ili
- oni koji pokazuju simptome alergije kada su izloženi travi.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0901928A GB0901928D0 (en) | 2009-02-05 | 2009-02-05 | Peptides for vaccine |
| GBGB0901927.4A GB0901927D0 (en) | 2009-02-05 | 2009-02-05 | Peptide for IL10 production |
| GB0912578A GB0912578D0 (en) | 2009-07-20 | 2009-07-20 | Peptide for IL-10 production |
| PCT/GB2009/001995 WO2010018384A1 (en) | 2008-08-15 | 2009-08-14 | T-cell antigen peptide from allergen for stimulation of il-10 production |
| GB0917871A GB0917871D0 (en) | 2009-10-12 | 2009-10-12 | Peptides for vaccine |
| EP10704399.4A EP2393830B8 (en) | 2009-02-05 | 2010-02-05 | Grass peptides for vaccine |
| PCT/GB2010/000198 WO2010089554A1 (en) | 2009-02-05 | 2010-02-05 | Peptides for vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150317T1 true HRP20150317T1 (hr) | 2015-04-24 |
Family
ID=42082585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150317TT HRP20150317T1 (hr) | 2009-02-05 | 2015-03-19 | Peptidi trave za cjepivo |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8753644B2 (hr) |
| EP (2) | EP2393830B8 (hr) |
| JP (2) | JP5746053B2 (hr) |
| KR (1) | KR20110111307A (hr) |
| CN (2) | CN103784952B (hr) |
| AU (1) | AU2010212193B2 (hr) |
| BR (1) | BRPI1008802A2 (hr) |
| CA (1) | CA2751500A1 (hr) |
| DK (1) | DK2393830T3 (hr) |
| EA (1) | EA020792B1 (hr) |
| ES (1) | ES2532759T3 (hr) |
| GB (1) | GB2469894B (hr) |
| HK (1) | HK1212358A1 (hr) |
| HR (1) | HRP20150317T1 (hr) |
| IL (1) | IL214257A (hr) |
| MX (1) | MX2011008179A (hr) |
| NZ (1) | NZ594268A (hr) |
| PL (1) | PL2393830T3 (hr) |
| PT (1) | PT2393830E (hr) |
| SG (1) | SG173523A1 (hr) |
| SI (1) | SI2393830T1 (hr) |
| WO (1) | WO2010089554A1 (hr) |
| ZA (1) | ZA201105436B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5746053B2 (ja) * | 2009-02-05 | 2015-07-08 | サーカッシア リミテッド | ワクチン用ペプチド |
| CN107261154A (zh) | 2011-04-29 | 2017-10-20 | 西莱克塔生物科技公司 | 致耐受性合成纳米载体 |
| AU2014262163A1 (en) | 2013-05-03 | 2015-11-19 | Selecta Biosciences, Inc. | Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance |
| EP3189138A4 (en) | 2014-09-07 | 2018-04-18 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses |
| US11013781B2 (en) | 2015-07-01 | 2021-05-25 | Alk-Abelló As | Peptide combinations and uses thereof for treating grass allergy |
| CA3055936A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| EP3672600A4 (en) | 2017-08-21 | 2021-05-19 | Glycom A/S | SYNTHETIC COMPOSITION TO REDUCE ALLERGY SYMPTOMS |
| CN108802216B (zh) * | 2018-05-23 | 2021-04-16 | 山东出入境检验检疫局检验检疫技术中心 | 一种使用区域敏感性蛋白组和/或多肽组鉴别刺参产地的方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340729C (en) | 1988-03-23 | 1999-09-07 | Mohan Bir Singh | Ryegrass pollen allergen |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| EP0576426B1 (en) | 1990-08-17 | 1997-10-22 | The University Of Melbourne | Ryegrass pollen allergen |
| WO1992016554A1 (en) | 1991-03-14 | 1992-10-01 | The University Of Melbourne | Protein allergens of the species cynodon dactylon |
| WO1994001560A1 (en) | 1991-07-12 | 1994-01-20 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from japanese cedar pollen |
| AU651728B2 (en) | 1991-08-16 | 1994-07-28 | University Of Melbourne, The | Ryegrass pollen allergen |
| US6441157B1 (en) | 1991-11-15 | 2002-08-27 | University Of Melbourne | Nucleic acid sequences encoding protein allergens of the species Cynodon dactylon |
| JP3618342B2 (ja) | 1991-11-15 | 2005-02-09 | ザ・ユニバーシティ・オブ・メルボルン | シノドン・ダクチロン（Ｃｙｎｏｄｏｎ ｄａｃｔｙｌｏｎ）種のタンパク質のアレルゲン |
| DE69333709T2 (de) | 1992-08-14 | 2006-05-11 | The University Of Melbourne, Parkville | T-zell epitope des raygraspollen-allergens |
| US6214358B1 (en) | 1992-10-30 | 2001-04-10 | Immulogic Pharamaceutical Corp. | Protein allergens of the species Cynodon dactylon |
| US5480972A (en) | 1992-10-30 | 1996-01-02 | The University Of Melbourne | Allergenic proteins from Johnson grass pollen |
| WO1994021675A2 (en) | 1993-03-12 | 1994-09-29 | Immulogic Pharmaceutical Corporation | T cell epitopes of ryegrass pollen allergen |
| NZ271818A (en) * | 1993-08-13 | 1997-11-24 | Immulogic Pharma Corp | T cell epitopes of ryegrass pollen antigen |
| US5820862A (en) | 1994-04-14 | 1998-10-13 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| GB9412714D0 (en) | 1994-06-24 | 1994-08-17 | Lewin Ian V | T cill epitopes |
| AU3338195A (en) * | 1994-07-26 | 1996-02-22 | University Of Manitoba | Allergen peptides |
| US7112333B1 (en) * | 1994-08-05 | 2006-09-26 | Heska Corporation | T cell epitopes of ryegrass pollen allergen |
| IL115744A (en) | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
| AT402505B (de) | 1995-08-02 | 1997-06-25 | Biomay Prod & Handel | Rekombinantes 60 kda pflanzliches panallergen (kofaktor-unabhängige phosphoglyceratmutase; e.c. 5.4.2.1.) |
| WO1999034826A1 (en) | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
| DE19823097A1 (de) * | 1998-05-22 | 1999-11-25 | Max Planck Gesellschaft | Mittel gegen saisonale Typ-I-Allergien und bakterielle Infektionen |
| US6989146B2 (en) | 2000-08-09 | 2006-01-24 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
| AUPR775401A0 (en) * | 2001-09-18 | 2001-10-11 | Monash University | Novel Epitopes and Uses Thereof |
| ATE414534T1 (de) | 2001-12-05 | 2008-12-15 | Circassia Ltd | Immunotherapeutische methoden und systeme |
| AUPS148202A0 (en) | 2002-04-02 | 2002-05-09 | Monash University | Immunotherapeutic and immunoprophylactic reagents |
| WO2003088997A2 (en) | 2002-04-22 | 2003-10-30 | Universiteit Utrecht Holding B.V. | Reduction of unwanted immune reactions |
| GB0210741D0 (en) | 2002-05-10 | 2002-06-19 | Medical Res Council | Methods of therapy |
| GB0308988D0 (en) | 2003-04-17 | 2003-05-28 | Univ Singapore | Molecule |
| DE102004035337A1 (de) * | 2004-07-21 | 2006-03-16 | Merck Patent Gmbh | Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität |
| WO2006075253A2 (en) | 2005-01-11 | 2006-07-20 | Commissariat A L'energie Atomique | Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides. |
| WO2006132607A1 (en) | 2005-06-10 | 2006-12-14 | National University Of Singapore | Mutant allergen(s) |
| DE202005009990U1 (de) * | 2005-06-25 | 2006-11-02 | Hengst Gmbh & Co.Kg | Vorrichtung zum Abscheiden von Ölteilchen aus dem Kurbelgehäuseentlüftungsgas einer Brennkraftmaschine |
| US20070092532A1 (en) | 2005-10-25 | 2007-04-26 | Board Of Trustees Operating Michigan State University | Arthritis vaccines and methods |
| US8748126B2 (en) | 2005-11-29 | 2014-06-10 | Actogenix N.V. | Induction of mucosal tolerance to antigens |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP2156183B1 (en) | 2007-05-09 | 2013-08-07 | Circassia Limited | Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| KR101699554B1 (ko) * | 2007-08-15 | 2017-01-25 | 서카시아 리미티드 | 백신용 펩티드 |
| EP2042193A1 (en) | 2007-09-28 | 2009-04-01 | Biomay AG | RNA Vaccines |
| EP2331124A1 (en) | 2008-08-15 | 2011-06-15 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
| JP5746053B2 (ja) * | 2009-02-05 | 2015-07-08 | サーカッシア リミテッド | ワクチン用ペプチド |
-
2010
- 2010-02-05 JP JP2011548765A patent/JP5746053B2/ja not_active Expired - Fee Related
- 2010-02-05 WO PCT/GB2010/000198 patent/WO2010089554A1/en active Application Filing
- 2010-02-05 MX MX2011008179A patent/MX2011008179A/es active IP Right Grant
- 2010-02-05 KR KR1020117019157A patent/KR20110111307A/ko not_active Application Discontinuation
- 2010-02-05 EA EA201171001A patent/EA020792B1/ru not_active IP Right Cessation
- 2010-02-05 CA CA2751500A patent/CA2751500A1/en not_active Abandoned
- 2010-02-05 CN CN201410056647.6A patent/CN103784952B/zh not_active Expired - Fee Related
- 2010-02-05 ES ES10704399.4T patent/ES2532759T3/es active Active
- 2010-02-05 SI SI201030898T patent/SI2393830T1/sl unknown
- 2010-02-05 EP EP10704399.4A patent/EP2393830B8/en active Active
- 2010-02-05 CN CN201080006665.3A patent/CN102307893B/zh not_active Expired - Fee Related
- 2010-02-05 SG SG2011055951A patent/SG173523A1/en unknown
- 2010-02-05 GB GB1001954A patent/GB2469894B/en active Active
- 2010-02-05 PL PL10704399T patent/PL2393830T3/pl unknown
- 2010-02-05 US US13/148,024 patent/US8753644B2/en active Active
- 2010-02-05 BR BRPI1008802A patent/BRPI1008802A2/pt not_active IP Right Cessation
- 2010-02-05 AU AU2010212193A patent/AU2010212193B2/en not_active Ceased
- 2010-02-05 PT PT107043994T patent/PT2393830E/pt unknown
- 2010-02-05 EP EP15152164.8A patent/EP2891662A1/en not_active Withdrawn
- 2010-02-05 DK DK10704399T patent/DK2393830T3/en active
- 2010-02-05 NZ NZ594268A patent/NZ594268A/xx not_active IP Right Cessation
-
2011
- 2011-07-22 ZA ZA2011/05436A patent/ZA201105436B/en unknown
- 2011-07-24 IL IL214257A patent/IL214257A/en not_active IP Right Cessation
-
2012
- 2012-01-10 HK HK16100075.0A patent/HK1212358A1/xx unknown
-
2014
- 2014-05-19 US US14/281,089 patent/US20140302071A1/en not_active Abandoned
-
2015
- 2015-03-19 HR HRP20150317TT patent/HRP20150317T1/hr unknown
- 2015-05-07 JP JP2015094636A patent/JP6215252B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150317T1 (hr) | Peptidi trave za cjepivo | |
| HRP20171909T1 (hr) | Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe | |
| RU2020111236A (ru) | Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности | |
| JP2015517488A5 (hr) | ||
| EA201490809A1 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| PE20240686A1 (es) | Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1) | |
| JP2011241213A5 (hr) | ||
| HRP20220717T1 (hr) | Modificirani pripravci mrna | |
| JP2015518818A5 (hr) | ||
| WO2008054540A3 (en) | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions | |
| AR093481A1 (es) | Parche de varios dias para la administracion transdermica de rotigotina | |
| BR112014008036A2 (pt) | tratamento de rinite | |
| CA2817787C (en) | Composition comprising a peptide and an inhibitor of viral neuraminidase | |
| RU2018120387A (ru) | Ангиотензин в лечении состояний головного мозга | |
| HRP20170794T1 (hr) | Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| BR112015000183A2 (pt) | proteínas de superfície específicas de variante (vsp) de protozoário como carreadores para entrega de fármaco oral | |
| PE20210116A1 (es) | Administracion oral de analogos del peptido glp-1 | |
| EP4349359A3 (en) | Peptide exhibiting wrinkle-improving activity and uses thereof | |
| RU2016114098A (ru) | Новое производное аналога инсулина | |
| BRPI1008103A2 (pt) | " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos " | |
| WO2013021284A3 (en) | Anti-il-6 vaccine composition | |
| RU2016135003A (ru) | Новые виды лечения | |
| WO2010086867A3 (en) | Peptides, pharmaceutical compositions comprising same and uses thereof | |
| HRP20171993T1 (hr) | Varijante ljudskog gdnf |